Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer

References

• NanavatyPAlvarezMSAlbertsWMLung cancer screening: advantages, controversies, and applicationsCancer Control201421191424357736
   PubMed Web of Science ®Google Scholar
• GkolfinopoulosSMountziosGBeyondEBeyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancerAnn Transl Med20186814229862231
   PubMed Web of Science ®Google Scholar
• EconomopoulouPMountziosGThe emerging treatment landscape of advanced non-small cell lung cancerAnn Transl Med20186813829862227
   PubMed Web of Science ®Google Scholar
• TeicherBATargets in small cell lung cancerBiochem Pharmacol201487221121924091017
   PubMed Web of Science ®Google Scholar
• TanakaKKumanoKUenoHIntracellular signals of lung cancer cells as possible therapeutic targetsCancer Sci2015106548949625707772
   PubMed Web of Science ®Google Scholar
• WoodSLPernemalmMCrosbiePAWhettonADMolecular histology of lung cancer: from targets to treatmentsCancer Treat Rev201541436137525825324
   PubMed Web of Science ®Google Scholar
• RiccardoFArigoniMBusonGCharacterization of a genetic mouse model of lung cancer: a promise to identify non-small cell lung cancer therapeutic targets and biomarkersBMC Genomics201415Suppl 3S1
   Web of Science ®Google Scholar
• PolitiKHerbstRSLung cancer in the era of precision medicineClin Cancer Res201521102213222025979927
   PubMed Web of Science ®Google Scholar
• SadiqAASalgiaRMET as a possible target for non-small-cell lung cancerJ Clin Oncol20133181089109623401458
   PubMed Web of Science ®Google Scholar
• ShawATOuSHBangYJCrizotinib in ROS1-rearranged non-small-cell lung cancerN Engl J Med2014371211963197125264305
   PubMed Web of Science ®Google Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell200713161190120318083107
   PubMed Web of Science ®Google Scholar
• RimkunasVMCrosbyKELiDAnalysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusionClin Cancer Res201218164449445722661537
   PubMed Web of Science ®Google Scholar
• CaiWLiXSuCROS1 fusions in Chinese patients with non-small-cell lung cancerAnn Oncol20132471822182723514723
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol201230886387022215748
   PubMed Web of Science ®Google Scholar
• RogersTMRussellPAWrightGComparison of methods in the detection of ALK and ROS1 rearrangements in lung cancerJ Thorac Oncol201510461161825789833
   PubMed Web of Science ®Google Scholar
• YoonHJSohnIChoJHDecoding tumor phenotypes for ALK, ROS1, and RET fusions in lung adenocarcinoma using a radiomics approachMedicine20159441e175326469915
   PubMed Web of Science ®Google Scholar
• UguenAde BraekeleerMROS1 fusions in cancer: a reviewFuture Oncol201612161911192827256160
   PubMed Web of Science ®Google Scholar
• ChinLPSooRASoongROuSHTargeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancerJ Thorac Oncol20127111625163023070242
   PubMed Web of Science ®Google Scholar
• DaviesKDLeATTheodoroMFIdentifying and targeting ROS1 gene fusions in non-small cell lung cancerClin Cancer Res201218174570457922919003
   PubMed Web of Science ®Google Scholar
• WuYLYangJCKimDWPhase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancerJ Clin Oncol201836141405141129596029
   PubMed Web of Science ®Google Scholar
• NiuXChuangJCBerryGJWakeleeHAAnaplastic lymphoma kinase testing: IHC vs. FISH vs. NGSCurr Treat Options Oncol201718127129143897
   PubMed Web of Science ®Google Scholar
• CaoBWeiPLiuZDetection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic featuresOnco Targets Ther2016913113826770062
   PubMed Web of Science ®Google Scholar
• BubendorfLBüttnerRAl-DayelFTesting for ROS1 in non-small cell lung cancer: a review with recommendationsVirchows Arch2016469548950327535289
   PubMed Web of Science ®Google Scholar
• KalemkerianGPNarulaNKennedyEBMolecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline UpdateJ Oncol Pract201814532332729589987
   PubMed Web of Science ®Google Scholar
• ArnaoutakisKCrizotinib in ROS1-rearranged non-small-cell lung cancerN Engl J Med20153727683
   Web of Science ®Google Scholar
• DaviesKDLeATSherenJComparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samplesJ Thorac Oncol201813101474148229935306
   PubMed Web of Science ®Google Scholar
• SchefflerMSchultheisATeixidoCROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityOncotarget2015612105771058525868855
   PubMedGoogle Scholar
• HongSGaoFFuSConcomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancerJAMA Oncol20184573974229596544
   PubMed Web of Science ®Google Scholar
• LiZShenLDingDEfficacy of crizotinib among different types of ROS1 fusion partners in patients with ROS1-rearranged non-small cell lung cancerJ Thorac Oncol201813798799529704675
   PubMed Web of Science ®Google Scholar
• XuTKangXYouXCross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from non-small cell lung carcinoma patient plasmaTheranostics2017761437144628529628
   PubMed Web of Science ®Google Scholar
• YangJJZhangXCSuJLung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationClin Cancer Res20142051383139224443522
   PubMed Web of Science ®Google Scholar
• WonJKKeamBKohJConcomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitorAnn Oncol201526234835425403583
   PubMed Web of Science ®Google Scholar
• SweisRFThomasSBankBFishkinPMooneyCSalgiaRConcurrent EGFR mutation and ALK translocation in non-small cell lung cancerCureus201682e51327026837
   PubMedGoogle Scholar
• LouNNZhangXCChenHJClinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsOncotarget2016740651856519527533086
   PubMedGoogle Scholar